Peptides
5-Amino-1MQ
Also called 5-amino-1MQ · 1MQ · 5-Amino-1-methylquinolinium
People look at 5-Amino-1MQ for fat loss without a stimulant or a weekly appetite injection. That appeal comes from an experimental metabolism target and animal results; reliable human weight-loss benefits and an effective dose have not been established.
Dosage & duration
One author’s published oral-use example, not a validated human regimen.
Jay Campbell · reported capsule use
Reported use · unapproved regimen- Dose
- 50–150 mg total per day
- How often
- Once daily, oral capsules
- How long
- 20–30 days, then a 1–2-week break in this example
The author describes personal use; this does not establish a common dose, proven benefit or safe course.
No human dose-response study in the checked sources validates this amount.
Why it attracts interest
A fat-loss idea with a human evidence gap
-
The appeal
People seek fat-loss support without a stimulant or weekly appetite injection.
-
The animal finding
The foundational weight-loss experiment used injections in mice.
-
The capsule question
That experiment does not establish human capsule benefits or an effective dose.
Why it is marketed for fat loss
5-Amino-1MQ blocks NNMT, an enzyme involved in cellular metabolism. The attraction is changing how the body handles energy rather than simply making someone less hungry. Mouse findings are a reason for research, not proof that a capsule accelerates human fat loss.
Where the capsule numbers come from
Clinic and seller pages publish oral amounts, while the foundational obesity experiment used injections in mice. A 50 mg capsule example is useful for understanding the market, but it is not a clinically established dose or a conversion from that animal experiment.
Comparing it with GLP-1 medicines
It is not a GLP-1 and it is not a peptide, despite often appearing in peptide catalogues. There is no verified head-to-head human trial here showing that it adds to a GLP-1 or preserves more muscle during weight loss.
Model details: 5-Amino-1MQ · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Human route/formulation, systemic exposure, absorption and terminal kinetics were not established by the reviewed source. Cell permeability cannot supply oral bioavailability.
- Neelakantan et al. 2018: NNMT inhibitors and diet-induced obesity
Cell permeability and mouse efficacy experiments do not provide matched human systemic Cmax, absorption or elimination parameters.
5-amino-1mq-relative-timing-2026-10 · version 1
Common questions
Is 5-Amino-1MQ a peptide?
No. It is a small molecule that inhibits NNMT.
Does a 50 mg capsule have proven weight-loss benefits?
The checked human evidence does not establish that. The displayed amount is an attributed clinic example.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- A sought-after benefit, not a proven human effect.
- Common format online
- Capsule claims are not the route used in the foundational mouse study.
- Important comparison
- Different target and much less clinical evidence.
- 1. Neelakantan et al. — NNMT inhibition in mice
Original obesity study used injected 5-amino-1MQ in mice, not human capsules.
- 2. Neelakantan et al. 2018: NNMT inhibitors and diet-induced obesity
Cell permeability and mouse efficacy experiments do not provide matched human systemic Cmax, absorption or elimination parameters.
Related compounds and examples
Related compounds
AICAR
AICAR for endurance: where the exercise-pill claim comes from, reported amounts and comparison with Cardarine.
SLU-PP-332
SLU-PP-332 draws interest for fat loss and endurance—the “exercise mimetic” idea. Mouse studies showed exercise-like metabolic changes, but they do not show that it replaces training or produces the same results in people. Human online experiments remain uncontrolled reports.
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.